Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Female Contraceptives Market - Expected to Reach $7 Billion by 2019 - Research and Markets

Research and Markets
Posted on: 06 Sep 17

The "Global Female Contraceptives Market 2017-2022" report has been added to Research and Markets' offering.

The global market for female contraceptives is estimated to be $4.71 billion in the year 2014. This market is expected to reach $7.09 billion by the end of 2019. During this period the market is estimated to grow at a CAGR of 8.53%.

Contributing to the growth of the contraceptives market globally is the necessity to avoid unwanted pregnancies and the complications. A high percentage of women who are sexually active do not want to become pregnant. This number is as high as 70% in the USA. The need to avoid unwanted pregnancies especially in the teenage women is one of the major drivers for this market. It is also observed that for more than half also identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain and acne, as reasons for use.

This is also one of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market is the increasing incidences of STDs and the rapid increase of the population globally. Government initiatives promoting the use of contraceptives to avoid unnecessary births and the health benefits from using the contraceptives have also been important players in the growth of the market.

Nevertheless, there are factors hindering the market prospects. Factors such as religious and cultural opposition in certain emerging nations have been restraining the growth of this market. Along with this, the fear of certain side effects and issues such as infertility resulting from the use of contraception has been major setbacks from the market point of view. Issues such as limited access to contraception in developing nations and economically backward nations have been another setback in this market. It is estimated that out of the global women population the need for contraceptive prevalence or meeting the needs of family planning is estimated to as high as 16.2%.

Companies Mentioned:

  • Bayer Healthcare
  • Pfizer
  • Merck & Co
  • Teva Pharmaceuticals, Ltd
  • Agile Therapeutics
  • Actavis PLC
  • ANI Pharmaceuticals, Inc
  • Church & Dwight, Co. Inc
  • Fuji Latex Co., Ltd
  • Johnson & Johnson, Ltd
  • Lupin Pharmaceuticals, Ltd
  • Okamato Industries, Inc.
  • Reckitt Beckinser Group, Plc
  • The Female Health Company
  • Mylan Laboratories

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Market Overview

4. Market Segmentation - Global Market for Female Contraceptive Drugs and Devices

5. Competitive Landscape

6. Company Profiles

7. Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 06/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.